222 related articles for article (PubMed ID: 32910430)
41. Progressive multifocal leukoencephalopathy: JC virus induced demyelination in the immune compromised host.
Hou J; Major EO
J Neurovirol; 2000 May; 6 Suppl 2():S98-S100. PubMed ID: 10871795
[TBL] [Abstract][Full Text] [Related]
42. Pembrolizumab treatment of inflammatory progressive multifocal leukoencephalopathy: a report of two cases.
Darcy S; Alexander M; McCarthy A; O'Dowd S
J Neurovirol; 2022 Feb; 28(1):145-150. PubMed ID: 34874539
[TBL] [Abstract][Full Text] [Related]
43. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
[TBL] [Abstract][Full Text] [Related]
44. The link between VLA-4 and JC virus reactivation.
Monaco MC; Major EO
Expert Rev Clin Immunol; 2012 Jan; 8(1):63-72. PubMed ID: 22149341
[TBL] [Abstract][Full Text] [Related]
45. [New trends in progressive multifocal leukoencephalopathy].
Gasnault J; Taoufik Y
Rev Neurol (Paris); 2006 Jan; 162(1):43-56. PubMed ID: 16446622
[TBL] [Abstract][Full Text] [Related]
46. Immune reconstitution inflammatory syndrome in a patient with progressive multifocal leukoencephalopathy.
Shahani L; Shah M; Tavakoli-Tabasi S
BMJ Case Rep; 2015 Jun; 2015():. PubMed ID: 26063110
[TBL] [Abstract][Full Text] [Related]
47. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases.
Boren EJ; Cheema GS; Naguwa SM; Ansari AA; Gershwin ME
J Autoimmun; 2008; 30(1-2):90-8. PubMed ID: 18191544
[TBL] [Abstract][Full Text] [Related]
48. New insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathy.
Bellizzi A; Anzivino E; Rodio DM; Palamara AT; Nencioni L; Pietropaolo V
Clin Dev Immunol; 2013; 2013():839719. PubMed ID: 23690827
[TBL] [Abstract][Full Text] [Related]
49. Rituximab-associated progressive multifocal leukoencephalopathy.
Sokol J; Lisá L; Zeleňáková J; Balhárek T; Plameňová I; Staško J; Kubisz P
Vnitr Lek; 2017; 63(1):60-64. PubMed ID: 28225293
[TBL] [Abstract][Full Text] [Related]
50. Progressive multifocal leukoencephalopathy in an elderly immunocompetent-appearing patient: Relevance with L-selectin (CD62L) expression and immunosenescence.
Boziki M; Metallidis S; Habidou E; Afrantou T; Bakirtzis C; Cheva A; Finitsis S; Grigoriadis N
Clin Neurol Neurosurg; 2021 Jun; 205():106625. PubMed ID: 33892220
[TBL] [Abstract][Full Text] [Related]
51. Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS).
Bauer J; Gold R; Adams O; Lassmann H
Acta Neuropathol; 2015 Dec; 130(6):751-64. PubMed ID: 26323992
[TBL] [Abstract][Full Text] [Related]
52. [Role of immunity in the development of progressive multifocal leukoencephalopathy: a report of three patients with type B lymphoma and humoral immunodeficiency and six others with acquired immunodeficiency syndrome].
Malkoun I; Vidry E; Revenco E; Drobacheff MC; Berger E; Rumbach L
Rev Neurol (Paris); 2006 Jan; 162(1):82-8. PubMed ID: 16446626
[TBL] [Abstract][Full Text] [Related]
53. Progressive multifocal leucoencephalopathy in a patient with idiopathic CD4+ lymphocytopenia.
Moloney F; Fernandez D; Harrington H
Ir Med J; 2012 Mar; 105(3):84-5. PubMed ID: 22558816
[TBL] [Abstract][Full Text] [Related]
54. Prevention and therapy of JC polyomavirus-mediated progressive multifocal leukoencephalopathy - a realistic possibility?
Jelcic I; Combaluzier B; Jelcic I; Sospedra M; Grimm J; Martin R
Swiss Med Wkly; 2017; 147():w14520. PubMed ID: 29120025
[TBL] [Abstract][Full Text] [Related]
55. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy.
Koralnik IJ; Du Pasquier RA; Letvin NL
J Virol; 2001 Apr; 75(7):3483-7. PubMed ID: 11238876
[TBL] [Abstract][Full Text] [Related]
56. HIV-associated progressive multifocal leukoencephalopathy: longitudinal study of JC virus non-coding control region rearrangements and host immunity.
Iannetta M; Bellizzi A; Lo Menzo S; Anzivino E; D'Abramo A; Oliva A; D'Agostino C; d'Ettorre G; Pietropaolo V; Vullo V; Ciardi MR
J Neurovirol; 2013 Jun; 19(3):274-9. PubMed ID: 23715894
[TBL] [Abstract][Full Text] [Related]
57. A combination of low-dose chlorpromazine and neutralizing antibodies inhibits the spread of JC virus (JCV) in a tissue culture model: implications for prophylactic and therapeutic treatment of progressive multifocal leukencephalopathy.
Atwood WJ
J Neurovirol; 2001 Aug; 7(4):307-10. PubMed ID: 11517408
[TBL] [Abstract][Full Text] [Related]
58. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
Reuwer AQ; Heron M; van der Dussen D; Schneider-Hohendorf T; Murk JL
Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
[TBL] [Abstract][Full Text] [Related]
59. BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study.
Cortese I; Beck ES; Al-Louzi O; Ohayon J; Andrada F; Osuorah I; Dwyer J; Billioux BJ; Dargah-Zada N; Schindler MK; Binder K; Reoma L; Norato G; Enose-Akahata Y; Smith BR; Monaco MC; Major EO; Jacobson S; Stroncek D; Highfill S; Panch S; Reich DS; Barrett J; Nath A; Muranski P
Lancet Neurol; 2021 Aug; 20(8):639-652. PubMed ID: 34302788
[TBL] [Abstract][Full Text] [Related]
60. Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control.
Schwab N; Ulzheimer JC; Fox RJ; Schneider-Hohendorf T; Kieseier BC; Monoranu CM; Staugaitis SM; Welch W; Jilek S; Du Pasquier RA; Brück W; Toyka KV; Ransohoff RM; Wiendl H
Neurology; 2012 Feb; 78(7):458-67; discussion 465. PubMed ID: 22302546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
